Ipamorelin

GHS-R1a Agonism: The Pulse Trigger#

Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that binds the growth hormone secretagogue receptor (GHS-R1a) — the same receptor ghrelin hits — on pituitary somatotrophs and hypothalamic neurons. Activation drives IP3/DAG signalling inside the somatotroph, depolarizes the cell, and triggers release of stored GH in a discrete pulse. At the hypothalamic level, it simultaneously amplifies endogenous GHRH tone and suppresses somatostatin (the brake on GH release), so you get a cleaner, taller pulse than GHRH-axis drugs can produce alone.

Practical upshot: ipamorelin doesn't add GH to your system — it makes your pituitary fire a natural-shape pulse on demand. That's why pre-bed dosing matters so much; you're stacking an extra trigger on top of the nocturnal surge your brain was already going to run.

Selectivity: Why It's the "Clean" GHRP#

The feature that made ipamorelin the default GHRP in physique circles is its receptor selectivity. Earlier generation GHRPs (GHRP-2, GHRP-6, hexarelin) drag cortisol, prolactin, and — in GHRP-6's case — hunger along for the ride. Ipamorelin doesn't.

"Ipamorelin is the first GHRP reported to be selective in vivo with no effects on plasma ACTH, cortisol, prolactin, FSH, LH or TSH concentrations, even at doses much higher than those required for maximal GH response." — Raun K. et al., European Journal of Endocrinology, 1998

For users running a long cycle, this is the whole argument: you can dose 2–3× daily for months without chronic cortisol elevation blunting recomp, without prolactin creeping into gyno/libido territory, and without the ravenous hunger that makes GHRP-6 unworkable in a cut.

Pulsatile GH Release and the IGF-1 Downstream#

Each injection produces a sharp, transient GH pulse that peaks around 40 minutes post-dose and decays to baseline inside 2–3 hours — mirroring the pulsatile architecture of native GH secretion rather than the flat, tonic elevation you get from recombinant HGH.

"The plasma GH concentration-time profiles after various doses of ipamorelin exhibited a dose-related peak value (Cmax) and an exponential decrease to baseline within 2-3 hr." — Gobburu J.V.S. et al., Pharmaceutical Research, 1999

The hepatic conversion of GH to IGF-1 is what delivers most of the downstream anabolic and recovery effects: nitrogen retention, soft-tissue repair, collagen synthesis, and modest lipolysis from the GH pulse itself before IGF-1 takes over. Expect a 20–50% rise in serum IGF-1 at effective dosing — meaningful, but nowhere near the 2–3× elevation achievable with 4–6 IU/day of rhGH. This is the fundamental ipamorelin vs HGH answer: same axis, smaller magnitude, far cleaner side-effect profile.

Pharmacokinetics and Why You Dose Multiple Times a Day#

After SubQ or IM administration ipamorelin is cleared quickly:

"After subcutaneous, intramuscular, or intravenous administration, ipamorelin was rapidly eliminated with an apparent terminal half-life of approximately 2 h and a volume of distribution similar to extracellular fluid." — Johansen P.B. et al., Xenobiotica, 1998

Two hours of peptide, ~90–120 minutes of GH pulse. That's the whole reason the community protocol is fractionated — AM fasted, pre/post-workout, pre-bed — rather than one big shot. Pituitary GH stores are also the rate limiter: past roughly 100 mcg/kg you saturate the response, which is why 300 mcg per injection is treated as a ceiling rather than a starting point. Spend your peptide on frequency, not per-shot dose.

Dietary fat and elevated free fatty acids blunt somatotroph response for 30–60 minutes, so injections go in fasted or ≥60 min after a fat-containing meal.

Connective Tissue, Bone, and Recovery Effects#

Beyond the headline muscle/fat-loss numbers, sustained pulsatile GH-axis stimulation drives collagen synthesis, chondrocyte activity, and bone turnover — which is where most users actually feel ipamorelin working.

"Compared with vehicle, ipamorelin increased tibial as well as total femoral bone length... The data confirm that ipamorelin stimulates longitudinal bone growth via a mechanism likely to involve the endogenous GH-IGF-I axis." — Johansen P.B. et al., Growth Hormone & IGF Research, 1999

Translated to practical outcomes: better sleep depth from the amplified nocturnal pulse, faster soft-tissue recovery between sessions, reduced joint dryness on heavy AAS cycles, and improved skin quality on longer runs. These are the effects driving the "pre-bed 200 mcg, run it indefinitely" protocol that's become standard in longevity and looksmaxxing stacks — the recovery and sleep score on this compound is where it genuinely punches above its weight.

Common (most users)#

• Transient head rush, flushing, or tingling in the 5–10 minutes post-injection — ghrelin-receptor mediated, fades with continued dosing. No action needed; if bothersome, split the dose or inject lying down.
• Injection-site redness or itch — minor and self-limiting. Rotate sites (abdomen, love handles, thigh), use fresh 29–31g insulin pins, and let the alcohol swab dry before injecting.
• Mild hunger bump — much weaker than GHRP-6 but still present in some users. Dose fasted or ≥60 min post-meal; if you're cutting, the pre-bed shot is the least disruptive.
• Grogginess on waking if the pre-bed dose is too large. Drop from 300 mcg → 200 mcg pre-bed and reassess.
• Vivid dreams / deeper sleep — technically a "side effect" but most users consider it a feature. No mitigation needed.

"Ipamorelin is the first GHRP reported to be selective in vivo with no effects on plasma ACTH, cortisol, prolactin, FSH, LH or TSH concentrations, even at doses much higher than those required for maximal GH response." — Raun et al., European Journal of Endocrinology (1998)

Uncommon (dose-dependent or individual)#

• Water retention, puffy hands/ankles, mild facial bloat — the classic GH-axis signal that your total daily dose is too high or the cycle has run too long. Drop to 200 mcg × 2/day or pull back to pre-bed only. Resolves within a week.
• Carpal-tunnel-type paresthesias (numb/tingly fingers overnight) — same mechanism, same fix. If it persists after dose reduction, stop and re-evaluate.
• Rising fasting glucose / blunted insulin sensitivity — chronic GH-axis stimulation is the mechanism. Pull fasting glucose and HbA1c at baseline, again at 8–12 weeks, and anytime you're stacking with exogenous rhGH or MK-677. If fasting glucose trends above ~100 mg/dL, reduce dose or cycle off.
• IGF-1 climbing above the upper end of the reference range — check IGF-1 at 4–6 weeks. A 20–50% rise from baseline confirms the product is real; a push well above age-normal range means back the dose off, especially if stacked with CJC-1295 or rhGH.
• Lethargy mid-cycle — usually receptor desensitization from continuous 3×/day dosing. A 5-on / 2-off week or a 2-week washout restores responsiveness.

Rare but serious#

• Worsening of pre-existing diabetic retinopathy — any GH-axis stimulator can accelerate proliferative retinopathy. New floaters, blurred vision, or visual field changes = stop immediately and get an ophtho exam.
• Accelerated growth of occult tumors — IGF-1 is mitogenic. Undiagnosed cancer is the concern here, not de-novo cancer risk. Unexplained weight loss, night sweats, palpable lumps, or persistent lymphadenopathy = stop and get worked up.
• Severe hypersensitivity reaction — peptide allergy is rare but exists. Hives, facial swelling, or respiratory symptoms post-injection = discontinue permanently.
• Frank hyperglycemia in susceptible individuals (prediabetic, insulin resistant, or stacked with rhGH + insulin) — stop dosing and recheck labs.

Hard contraindications#

• Active malignancy or recent cancer history — do not run any GH/IGF-axis compound.
• Active proliferative diabetic retinopathy.
• Uncontrolled diabetes — stabilize glycemic control first.
• Pregnancy and lactation.
• Known hypersensitivity to ipamorelin or other ghrelin-mimetic peptides.
• Stacking ipamorelin with MK-677 — both hit GHS-R1a; you get receptor desensitization and no additive benefit. Run one or the other.

Gender considerations and PCT#

Ipamorelin is non-hormonal and non-suppressive — no HPTA impact, no aromatization, no androgen receptor activity. PCT is not required and no ancillaries are needed. Men and women use it identically; women often find the lower end of the range (100–200 mcg per injection) sufficient. It is genuinely one of the best-tolerated compounds in the peptide space, and the selectivity profile — no cortisol, no prolactin, no LH/FSH disruption — is the reason it has displaced GHRP-2 and GHRP-6 as the default GHRP in community protocols.